TNFSF11 and osteoporosis: We also demonstrated that targeting of OLCs via administration of bisphosphonates, which are commonly used to treat osteoporosis, or RANKL-neutralizing antibody, decreased aneurysmal dilation in the mouse CaPO4 and AngII models, respectively [18,22].